UmeclidiniumMeSH concept

https://www.has-sante.fr/jcms/p_3589929/fr/zen-o-lite
2025
France
health technology assessment
oxygen, nos
oxygen
concentration
mobility, nos
umeclidinium
attention

---
https://www.chu-lyon.fr/traitement-par-catechol-o-methyl-transferase-icomt
2024
France
popular works
umeclidinium
catechol, nos
catechol
Catechol O-Methyltransferase Inhibitors
catechol
transferase, nos
catechols
methylation
transferases

---
https://www.infectiologie.com/fr/actualites/gericco-2024_-n.html
2024
France
congresses
Epidemiology Research
infectious disease medicine
Clark Level I
biomedical research
Blood Group O
Pooled Sample
Iodine
Stage I Bladder Cancer AJCC v8
Oxygen
Exa
ISS Stage I Multiple Myeloma
NIH Clinical Center
epidemiology
population groups
Pool
West
Stage I Intrahepatic Cholangiocarcinoma AJCC v8
Stage I Cervical Cancer AJCC v8
epidemiologic research design
Pathologic Stage I Esophageal Adenocarcinoma AJCC v8
Inch
Infectious Diseases Research
Stage I Prostate Cancer AJCC v8
Pooled Blood Products
Be
academies and institutes
Beryllium
IRS Clinical Grouping System
Stage I Uveal Melanoma AJCC v7
Iodide
Clinical Study
Elementary Charge
Stage Grouping
Osmium
MATCH Arm EAY131-E
central
MATCH Arm EAY131-I
umeclidinium
Stage I Distal Bile Duct Cancer AJCC v8
research
Stage I Hilar Cholangiocarcinoma AJCC v8

---
https://www.hgr-css.be/fr/avis/9763/lutilisation-eclairee-du-sang-o-negatif
2024
Belgium
public health guidelines
CDH1 Gene Mutation Negative
Wnt Negative
KIT Negative
Oxygen
Osmium
Use
Negative Lymph Node
Unmethylated MGMT Gene Promoter
GNA11 Gene Mutation Negative
Blood Sample
Epstein-Barr Virus Negative
Hepatitis B Virus Surface Antigen Negative
umeclidinium
BAP1 Gene Mutation Negative
TERT Promoter Mutation Negative
lightning
KRAS Gene Mutation Negative
Negative Number
ATRX Gene Mutation Negative
ERBB2 Gene Amplification Negative
ERBB2 Gene Mutation Negative
Blood Group O
FGFR2 Gene Mutation Negative
Blood
PAX8 Gene Rearrangement Negative
Hepatitis B Surface Antibody Negative
Hepatitis B Virus Core Antibody Negative
blood
ESR2 Negative
FGFR2 Gene Rearrangement Negative
Progesterone Receptor Negative
IDH Family Wildtype
Human Immunodeficiency Virus Negative
Lack of Expression of PD-L1
NRAS Gene Mutation Negative
ERG Gene Rearrangement Negative
FGFR3 Gene Mutation Negative
RET Gene Rearrangement Negative
Murine Blood
GNAQ Gene Mutation Negative
FGFR3 Gene Rearrangement Negative
10q23/PTEN Locus Deletion Negative
ANO1 Negative
CDKN2A-p16 Negative
SDHA Negative
lighting
CTNNB1 Gene Mutation Negative
SDHB Negative
Beryllium
Be
HRAS Gene Mutation Negative
PAS Negative
Negative Charge
BRAF Gene Mutation Negative
FGFR1 Gene Mutation Negative
ETV Gene Rearrangement Negative
lightning

---
https://www.has-sante.fr/jcms/p_3332764/fr/elebrato-ellipta-furoate-de-fluticasone-/-bromure-d-umeclidinium-/-trifenatate-de-vilanterol-bpco
2022
false
false
false
France
drug combinations
vilanterol, umeclidinium bromide and fluticasone furoate
fluticasone furoate
umeclidinium
pulmonary disease, chronic obstructive
evaluation of the transparency committee
vilanterol

---
https://www.has-sante.fr/jcms/p_3332759/fr/trelegy-ellipta-furoate-de-fluticasone/-bromure-d-umeclidinium-/-trifenatate-de-vilanterol-bpco
2022
false
false
false
France
French
evaluation of the transparency committee
bromides
registries
chronic obstructive lung disease, nos
vilanterol
vilanterol trifenatate
bromide salt, nos
umeclidinium
vilanterol
pulmonary disease, chronic obstructive
bromination
halogenation

---
https://www.has-sante.fr/jcms/p_3340190/fr/zen-o-clarity-rs-00500c
2022
France
health technology assessment
mobility, nos
umeclidinium
oxygen, nos
oxygen
concentration
attention

---
https://www.has-sante.fr/jcms/p_3373594/fr/zen-o-lite-clarity
2022
France
health technology assessment
umeclidinium
attention
concentration
mobility, nos
oxygen
oxygen, nos

---
https://www.has-sante.fr/jcms/p_3332874/fr/zen-o-rs-00500
2022
France
health technology assessment
attention
oxygen, nos
concentration
oxygen
mobility, nos
umeclidinium

---
https://www.has-sante.fr/jcms/p_3191672/fr/laventair-ellipta
2020
false
false
false
France
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
vilanterol
Vilanterol Trifenatate
evaluation of the transparency committee
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes

---
https://www.has-sante.fr/jcms/p_3191675/fr/anoro-ellipta
2020
false
false
false
France
drug combinations
umeclidinium
vilanterol
vilanterol and umeclidinium bromide
evaluation of the transparency committee
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes

---
https://www.has-sante.fr/portail/jcms/c_2964750/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines

---
https://www.has-sante.fr/portail/jcms/c_2964753/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
fluticasone furoate
fluticasone furoate
glucocorticoids
glucocorticoids
umeclidinium
umeclidinium
muscarinic antagonists
muscarinic antagonists
vilanterol
vilanterol
pulmonary disease, chronic obstructive
product surveillance, postmarketing
vilanterol, umeclidinium bromide and fluticasone furoate
administration, inhalation
adult
aged
drug interactions
pregnancy
breast feeding
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines
androstadienes
androstadienes
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes

---
https://www.has-sante.fr/portail/jcms/c_2847883/fr/elebrato-trelegy-ellipta
2018
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines

---
Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Trelegy-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes

---
Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Elebrato-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes

---
http://www.has-sante.fr/portail/jcms/c_2754746/fr/laventair
2017
false
false
false
France
French
treatment outcome
umeclidinium
vilanterol
vilanterol and umeclidinium bromide
drug combinations
administration, inhalation
bronchodilator agents
pulmonary disease, chronic obstructive
adult
muscarinic antagonists
adrenergic beta-2 receptor agonists
evaluation of the transparency committee
insurance, health, reimbursement
GSK573719
benzyl alcohols
chlorobenzenes
quinuclidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Rolufta
2017
false
false
false
United Kingdom
French
English
adult
pulmonary disease, chronic obstructive
package leaflet
syndication feed
drug evaluation
summary of product characteristics
umeclidinium
umeclidinium
drug approval
europe
treatment outcome
umeclidinium bromide
administration, inhalation
muscarinic antagonists
muscarinic antagonists
drug interactions
pregnancy
breast feeding
clinical trials, phase iii as topic
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines

---
http://www.has-sante.fr/portail/jcms/c_2676741/fr/anoro
http://www.has-sante.fr/portail/jcms/c_2676741/fr/anoro-bromure-d-umeclidinium-/-vilanterol-anticholinergique-/-agoniste-beta2-adrenergique-de-longue-duree-d-action
2016
false
false
false
France
French
evaluation of the transparency committee
drug combinations
vilanterol and umeclidinium bromide
insurance, health, reimbursement
treatment outcome
pulmonary disease, chronic obstructive
adult
bronchodilator agents
guidelines for drug use
vilanterol
umeclidinium
vilanterol trifenatate
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes

---
http://www.has-sante.fr/portail/jcms/c_2606854/fr/incruse
2016
false
false
false
France
French
adult
pulmonary disease, chronic obstructive
umeclidinium
umeclidinium
treatment outcome
umeclidinium bromide
administration, inhalation
muscarinic antagonists
muscarinic antagonists
bronchodilator agents
bronchodilator agents
evaluation of the transparency committee
GSK573719
GSK573719
quinuclidines
quinuclidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Laventair
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
umeclidinium
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
drug monitoring
product surveillance, postmarketing
drug approval
europe
administration, inhalation
bronchodilator agents
bronchodilator agents
pulmonary disease, chronic obstructive
adult
aged
drug interactions
pregnancy
breast feeding
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials as topic
drug evaluation, preclinical
GSK573719
GSK573719
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
quinuclidines
quinuclidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Incruse
2014
false
false
false
United Kingdom
French
English
adult
pulmonary disease, chronic obstructive
package leaflet
syndication feed
drug evaluation
summary of product characteristics
umeclidinium
umeclidinium
drug approval
europe
treatment outcome
umeclidinium bromide
administration, inhalation
muscarinic antagonists
muscarinic antagonists
drug interactions
pregnancy
breast feeding
clinical trials, phase iii as topic
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines

---
Summary Basis of Decision (SBD) for Anoro Ellipta
Umeclidinium bromide and vilanterol trifenatate 62.5 µg of umeclidinium (as umeclidinium bromide) and 25 µg of vilanterol (as vilanterol trifenatate) Powder, oral inhalation
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00270
2014
false
false
false
Canada
French
English
summary of product characteristics
drug approval
canada
drug combinations
administration, inhalation
treatment outcome
drug evaluation
risk assessment
clinical trials as topic
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
umeclidinium
bronchodilator agents
bronchodilator agents
Delayed-Action preparations
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
pulmonary disease, chronic obstructive
bronchitis, chronic
pulmonary emphysema
adult
aged
GSK573719
GSK573719
quinuclidines
quinuclidines
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes

---
https://www.ema.europa.eu/medicines/human/EPAR/Anoro
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
umeclidinium
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
drug monitoring
product surveillance, postmarketing
drug approval
europe
administration, inhalation
bronchodilator agents
bronchodilator agents
pulmonary disease, chronic obstructive
adult
aged
drug interactions
pregnancy
breast feeding
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials as topic
drug evaluation, preclinical
drug evaluation
GSK573719
GSK573719
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
quinuclidines
quinuclidines

---